Accordingly, complement inhibitors are considered as promising therapeutic options during the ongoing SARS-CoV-2 pandemic (14, 15), and the first COVID-19 cases treated by the C5 inhibitor monoclonal antibody eculizumab (16–18), and by the C3-targeting small peptide inhibitor AMY-101 (19) have recently been reported. This evidence concerns the gene C5 and COVID-19.